TG Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 01, 2023 at 12:15 pm
Share
TG Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 16.07 million compared to USD 0.594 million a year ago. Net loss was USD 47.61 million compared to USD 40.51 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.3 a year ago.
For the six months, revenue was USD 23.88 million compared to USD 2.61 million a year ago. Net loss was USD 86.84 million compared to USD 109.52 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.81 a year ago.
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
TG THERAPEUTICS, INC. 
